Apply for Funding

Investment Opportunities | Investment Process |


|Investment Opportunities

Grants

Current Open RFP

GHIT Fund RFP Product Development Platform 2017-002

The GHIT Fund announces an investment opportunity for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration projects should be no more than two years in duration and may focus on a broad array of R&D activities, including:

 

- Lead optimization

- Preclinical Development (in-vivo studies, formulation development, chemistry and process validation)

- Clinical Development (Phase 1, 2, or 3 studies, manufacturing scale-up)

- Activities to support licensure and WHO prequalification

 

Interested applicants can find detailed information on the RFP and the Intent to Apply form below.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

July 25, 2017

Intent to Apply

No later than 10:00 am Tokyo time on August 21, 2017

Submit via Editorial Manager® for Product Development Platform

(http://www.editorialmanager.com/ghitfund/)

Q&A

No later than 10:00 am Tokyo time on August 17, 2017

Submit questions to RFPResponse@ghitfund.org

Email Subject Line: GHIT-RFP-PD-2017-002_Questions

Full Proposal Due

No later than 10:00 am Tokyo time on September 19, 2017

Submit via Editorial Manager® for Product Development Platform

(http://www.editorialmanager.com/ghitfund/)

Proposals Evaluation and Interview Processes

September 2017 - February 2018

Award Notification to All Applicants

February 2018

Investment Agreement Fully Executed (Awarded Proposals)

March 2018

Past RFP

GHIT Fund RFP Product Development Platform 2017-001

The GHIT Fund announces an investment opportunity for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration projects should be no more than two years in duration and may focus on a broad array of R&D activities, including:

 

- Lead optimization

- Preclinical Development (in-vivo studies, formulation development, chemistry and process validation)

- Clinical Development (Phase 1, 2, or 3 studies, manufacturing scale-up)

- Activities to support licensure and WHO prequalification

 

Interested applicants can find detailed information on the RFP and the Intent to Apply form below.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

October 7, 2016

Intent to Apply

No later than 10:00 am Tokyo time on November 10, 2016

Submit via Editorial Manager® for Product Development Platform

(http://www.editorialmanager.com/ghitfund/)

Q&A

No later than 10:00 am Tokyo time on December 26, 2016

Submit questions to RFPResponse@ghitfund.org

Email Subject Line: GHIT-RFP-PD-2017-001_Questions

Full Proposal Due

No later than 10:00 am Tokyo time on January 13, 2017

Submit via Editorial Manager® for Product Development Platform

(http://www.editorialmanager.com/ghitfund/)

Proposals Evaluation and Interview Processes

January 2017 - July 2017

Award Notification to All Applicants

End of July 2017

Investment Agreement Fully Executed (Awarded Proposals)

Mid-September 2017

GHIT Fund RFP Product Development Platform 2016-002

The GHIT Fund announces an investment opportunity for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration projects should be no more than two years in duration and may focus on a broad array of R&D activities, including:

- Lead optimization

- Preclinical Development (in-vivo studies, formulation development, chemistry and process validation)

- Clinical Development (Phase 1, 2, or 3 studies, manufacturing scale-up)

- Activities to support licensure and WHO prequalification

Interested applicants can find detailed information on the RFP and the Intent to Apply form below.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

July 1, 2016

Intent to Apply

No later than 10:00 am Tokyo time on July 28, 2016

Submit via Editorial Manager® for Product Development

Platform (http://www.editorialmanager.com/ghitfund/)

Q&A

No later than 10:00 am Tokyo time on August 23, 2016

Submit questions to RFPResponse@ghitfund.org

Email Subject Line: GHIT-RFP-PD-2016-002_Questions

Full Proposal Due

No later than 10:00 am Tokyo time on September 1, 2016

Submit via Editorial Manager® for Product Development

Platform (http://www.editorialmanager.com/ghitfund/)

Award Notification to All Applicants

No later than February 10, 2017

GHIT Fund RFP Product Development Platform 2016-001

The GHIT Fund announces an investment opportunity for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration projects should be no more than two years in duration and may focus on a broad array of R&D activities, including:

 

- Lead optimization

- Preclinical Development (in-vivo studies, formulation development, chemistry and process validation)

- Clinical Development (Phase 1, 2, or 3 studies, manufacturing scale-up)

- Activities to support licensure and WHO prequalification

 

If you are interested in applying for the platform, please see RFP.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

October 1, 2015

Intent to Apply

No later than 10:00 am Tokyo time on November 16, 2015 Submit via Editorial Manager® for Product Development Platform (http://www.editorialmanager.com/ghitfund/)

Q&A

No later than 10:00 am Tokyo time on December 18, 2015 Submit questions to RFPResponse@ghitfund.org 
Email Subject Line: GHIT-RFP-PD-2016-001_Questions

Full Proposal Due

No later than 10:00 am Tokyo time on January 6, 2016 Submit via Editorial Manager® for Product Development Platform (http://www.editorialmanager.com/ghitfund/)

Award Notification to All Applicants

No later than August 1, 2016

GHIT Fund RFP Product Development Platform 2015-002

The GHIT Fund announces an investment opportunity for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration projects should be no more than two years in duration and may focus on a broad array of R&D activities, including:

 

- Lead optimization

- Preclinical Development (in-vivo studies, formulation development, chemistry and process validation)

- Clinical Development (Phase 1, 2, or 3 studies, manufacturing scale-up)

- Activities to support licensure and WHO prequalification

 

If you are interested in applying for the platform, please see RFP.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

June 22, 2015

Intent to Apply

No later than 10:00 am Tokyo time on August 5, 2015

Submit via Editorial Manager® for Product Development Platform

 

Q&A

No later than 10:00 am Tokyo time on September 1, 2015

Submit questions to RFPResponse@ghitfund.org

Email Subject Line: GHIT-RFP-PD-2015-002_Questions

Full Proposal Due

No later than 10:00 am Tokyo time on September 9, 2015

Submit via Editorial Manager® for Product Development Platform 

Award Notification to All Applicants

No later than February 12, 2016

GHIT Fund RFP Product Development Platform 2015-001

The GHIT Fund announces an investment opportunity for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration projects should be no more than two years in duration and may focus on a broad array of R&D activities, including:

 

- Lead optimization

- Preclinical Development (in-vivo studies, formulation development, chemistry and process validation)

- Clinical Development (Phase 1, 2, or 3 studies, manufacturing scale-up)

- Activities to support licensure and WHO prequalification

 

If you are interested in applying for the platform, please see RFP.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

February 6, 2015

Intent to Apply
No later than 10:00 am Tokyo time on March 13, 2015
 
Q&A
No later than 10:00 am Tokyo time on March 30, 2015
Submit questions to RFPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-PD-2015-001_Questions
Full Proposal Due
No later than 10:00 am Tokyo time on April 3, 2015
Award Notification to All Applicants

No later than August 1, 2015

GHIT Fund RFP Product Development Platform 2014-002

The GHIT Fund announces a funding award opportunity for the development of new medicines, vaccines, or diagnostics for neglected tropical diseases (NTDs) that are prevalent in the developing world. Proposed projects should address NTD-related health needs in the developing world or fill a gap in global health technologies focused on NTDs. 

 

In April 2014, the GHIT Fund endorsed the 2012 London Declaration on Neglected Tropical Diseases and joined its signatories, representing NGOs, pharmaceutical companies, government agencies, and academic-research sectors, in commitment to the eradication, elimination, and control of NTDs in the world’s poorest populations. In line with this commitment, This RFP will focus specifically on “Combatting Neglected Tropical Diseases (NTDs)."

(For your referernce; www.ghitfund.org/about/mediacenter/pressdetail/detail/81)

 

The proposed collaboration project may include R&D activities from pre-clinical research (post-lead optimization) through licensure. More specifically, we seek to fund a portfolio of innovative collaboration projects, such as:

      ■ Pre-clinical development (e.g., lead-optimization, in-vivo studies, formulation development, chemistry and process validation)

      ■ Clinical development (e.g., Phase 1, Phase 2, Phase 3, manufacturing scale up)

      ■ Activities to support licensure and WHO pre qualification 

 

If you are interested in applying for the grant, please download RFP related documents.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

13th June, 2014

Intent to Apply

From 10:00am Tokyo Time on 16th June, 2014

To 10:00 am Tokyo Time on 18th August, 2014

Submit GHIT RFP 2014-002 Intent To Apply using our online submission system (http://www.editorialmanager.com/ghitfund/)

Q&A

Submit Questions to RFPResponse@ghitfund.org no later than 11th September, 2014.

Email Subject Line: GHIT Fund-RFP-2014-002 Questions

Full Proposal Due

No later than 10:00 am Tokyo Time on 18th September, 2014

Award Notification to All Applicants

No later than 16th February, 2015

GHIT Fund RFP Product Development Platform 2014-001

The GHIT Fund announces a funding award opportunity for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration project may include R&D activities from pre-clinical research (post-lead optimization) through licensure. More specifically, we seek to fund a portfolio of innovative collaboration projects, such as:

  • ・Pre-clinical development (e.g., lead-optimization, in-vivo studies, formulation development, chemistry and process validation)
  • ・Clinical development (e.g., Phase 1, Phase 2, Phase 3, manufacturing scale up)
  • ・Activities to support licensure and WHO prequalification

If you are interested in applying for the grant, please download RFP related documents.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

February 3, 2014

Intent to Apply

10:00 am March 17, 2014
Submit GHIT_RFP_IntentToApply.doc to RFPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-2014-001 Intent to Apply

Q&A

Submit Questions to RFPResponse@ghitfund.org
no later than 10:00 am April 7, 2014
Email Subject Line: GHIT-RFP-2014-001 Questions

Full Proposal Due

10:00 am Tokyo Time April 15, 2014

Award Notification to All Applicants

No later than September 1, 2014

GHIT Fund RFP Product Development Platform 2013-002

The GHIT Fund announces a funding award opportunity for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration project may include R&D activities from pre-clinical research (post-lead optimization) through licensure. More specifically, we seek to fund a portfolio of innovative collaboration projects, such as:

  • ・Pre-clinical development (e.g., lead-optimization, in-vivo studies, formulation development, chemistry and process validation)
  • ・Clinical development (e.g., Phase 1, Phase 2, Phase 3, manufacturing scale up)
  • ・Activities to support licensure and WHO prequalification

If you are interested in applying for the grant, please download RFP related documents.


RFP and Intent to Apply

GHIT Fund RFP Product Development Platform 2013-001

The GHIT Fund announces a funding award opportunity for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration project may include R&D activities from pre-clinical research (post-lead optimization) through licensure. More specifically, we seek to fund a portfolio of innovative collaboration projects, such as:

  • ・Pre-clinical development (e.g., lead-optimization, in-vivo studies, formulation development, chemistry and process validation)
  • ・Clinical development (e.g., Phase 1, Phase 2, Phase 3, manufacturing scale up)
  • ・Activities to support licensure and WHO prequalification

If you are interested in applying for the grant, please download RFP related documents.


RFP and Intent to Apply

RFP Schedule

GHIT Fund RFP Schedule of Product Development

2016-002

RFP ReleaseJuly, 2016
ITAJuly, 2016
ProposalSep, 2016
Award NotificationFeb, 2017
AgreementMar, 2017

|Investment Process

process1

Applicants

ITA Submission

Interested applicants must complete the Intent to Apply (ITA) form and submit this to the GHIT Fund via Editorial Manager®, an online document submission system dedicated for this funding program within an RFP-specified timeframe. Please note that ITA documents or Proposals that are not submitted through the above-mentioned system will not be accepted. An ITA form will be posted on the GHIT Fund website when the RFP is released.

process2

Management Team

Eligibility Review

Applicants who successfully submit the ITA document will receive a confirmation email. GHIT Fund staff will then perform an initial partnership and scope eligibility assessment. Eligible applicants will receive a confirmation email with GHIT Fund Proposal, Timeline, and Budget templates to support proposal development. If the project does not meet the eligibility requirements, the applicant will be notified that the project as proposed is not eligible for consideration. Applicants can remedy any eligibility issues and resubmit an ITA form up until the RFP-designated due date.

process3

Applicants

Full Proposal Submission

Applicants are required to submit their completed proposals to the GHIT Fund via Editorial Manager®. Applicants who successfully submit their proposal document will receive a confirmation email. Proposals may not be modified after the submission due date. Proposals will initially be examined to determine whether

  • The partnership meets GHIT Fund eligibility criteria
  • Project objectives are aligned with the RFP-specified scope
  • The proposal is complete and addresses all required content

process4

External Reviewers

Review

Each eligible proposal will be reviewed by 3 external reviewers, including experts in the discovery and development of global health technologies, each of whom possesses the experience to objectively evaluate the proposal content. External reviewers are required to declare that they have no relation to the applicants and use a proposal evaluation tool to consistently assess the quality of proposals. All proposals passing the preliminary examination will be evaluated and prioritized based on the following criteria:

  • Scientific and technical merit (e.g., sound approach and methodology, level of innovation, overall quality and comprehensiveness)
  • Potential Impact (e.g., how it will address a global health priority)
  • Partnership and project management (e.g., collaboration capabilities and expertise, project history and performance, risk management, budget)

process5

Selection Committee

Interactive Interview and Request approval for funding recommendation

Based on the aggregated External Reviewer results and a subsequent evaluation by the GHIT Fund Selection Committee (SC), proposals will be ranked by evaluation score. The top-tier applicants will be invited for an interactive interview with the SC. The GHIT SC will then critique each proposal, assess the quality of each product development plan, and recommend funding to the Board.

process6

Board of Directors

Review and approve funding recommendation

Proposals selected by the SC will be passed to the GHIT Fund Board of Directors whose members review and approve investment award decisions. The GHIT Board directs portfolio strategy and awards funding using a milestone-based approach to ensure return with minimal risk.

process7

Management Team and Product Development Partners

Award Notification, Investment Agreement and Investment

The GHIT Fund will notify applicants of their selection status by email. If the proposal is selected and the applicant receives an award notification, they are required to sign the Investment Agreement with the GHIT Fund and also submit a collaboration partners contractual agreement which clearly defines the roles and responsibilities of all collaboration partners, within one month from award notification. Please be aware that the award may be void if this condition is not met. Applicants are required to identify the designated development partner (investment recipient) and all other collaboration partners. The designated development partner will be responsible for the performance of all its collaborating partners. A representative of the designated development partner will serve as the main GHIT Fund point of contact and will be responsible for all GHIT Fund discussions and negotiations.

process8

Management Team

Initiation of Monitoring and Evaluation

Once the agreement enters into effect, the GHIT Management Team will initiate Monitoring and Evaluation process. The data and information regarding the project will be put into the system.

process9

Management Team and Product Development Partners

Monitoring and Evaluation

To track the progress of each project, GHIT conducts progress updates twice a year. This enables us to keep track of the progress of investments and decide on whether to continue, modify, or terminate the investment contingent upon milestone achievement. With this system, data pertaining to the progress of each project is gathered via an electronic system and the GHIT Management Team holds a conference with all product development partners based on the collected data prior to the meeting.